Stock Report

Download full stock data and analysis for free Last Updated: 08-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Kalvista Pharmaceuticals Inc (KALV)

Stock Card factsheet share-fund-plan-icon

$26.72

$0.00 (0.00%)

As on 07-May-2026 16:03EDT

Market cap

info icon

$1,421 Mln

Revenue (TTM)

info icon

$61 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

49

Div. Yield

info icon

0 %

Kalvista Pharmaceuticals Inc (KALV) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio
NASDAQ
NASDAQ

Stock Range

Today’s Range

Low: 26.70 High: 26.74

52 Week Range

Low: 9.83 High: 26.85

Liquidityliquidity Moderate

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -1.9 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -3.5

  • Debt to EquityDebt to Equity information

    --

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    53,167,988

10 Years Aggregate

CFO

$-339.49 Mln

EBITDA

$-402.86 Mln

Net Profit

$-341.35 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Kalvista Pharmaceuticals Inc (KALV)
65.4 32.3 85.6 113.9 40.6 1.5 9.9
BSE Sensex*
-8.6 3.8 -7.4 -4.1 8.2 9.5 11.9
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 07-May-2026  |  *As on 08-May-2026  |  #As on 26-Oct-2023
Company
2025
2024
2023
2022
2021
2020
2019
Kalvista Pharmaceuticals Inc (KALV)
90.7 -30.6 81.2 -48.9 -30.3 6.6 -9.8
S&P Small-Cap 600
4.0 7.0 13.9 -17.4 25.3 9.6 20.9
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Kalvista Pharmaceuticals Inc (KALV)

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of...  acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. Address: 200 Crossing Boulevard, Framingham, MA, United States, 01702  Read more

  • CEO & Director

    Mr. Benjamin L. Palleiko

  • CEO & Director

    Mr. Benjamin L. Palleiko

  • Headquarters

    Framingham, MA

  • Website

    https://www.kalvista.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Kalvista Pharmaceuticals Inc (KALV)

The share price of Kalvista Pharmaceuticals Inc (KALV) is $26.72 (NASDAQ) as of 07-May-2026 16:03 EDT. Kalvista Pharmaceuticals Inc (KALV) has given a return of 40.57% in the last 3 years.

Since, TTM earnings of Kalvista Pharmaceuticals Inc (KALV) is negative, P/E ratio is not available.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2026
--
--
2025
--
--
2024
--
--
2023
--
--
2022
--
--

The 52-week high and low of Kalvista Pharmaceuticals Inc (KALV) are Rs 26.85 and Rs 9.83 as of 08-May-2026.

Kalvista Pharmaceuticals Inc (KALV) has a market capitalisation of $ 1,421 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Kalvista Pharmaceuticals Inc (KALV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.